

Please type a plus sign (+) in this box ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number 09/424,940

Filing Date 12/03/99

First Named Inventor Cress et al.

Group Art Unit unknown

Examiner Name unknown

Attorney Docket Number 212662-11

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publications of Cited Documents MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Class	Subclass			
GW	AA	5,599,678	-	-	Kraus, et al.	02/04/97	
GW	AB	5,591,595	-	-	Aken, et al.	01/07/97	
GW	AC	4,628,027	-	-	Gay	12/09/86	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publications of Cited Documents MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
GW	BA	PCT	WO 98/55872		AMDL, Inc.	12/10/98		N

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ⁷	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GW	CA	AMIRAL, J. et al., Monoclonal Antibodies to Different Neo-epitopes on Fibrinogen and Fibrin Degradation Products, <i>Blood Coagulation and Fibrinolysis</i> , Vol. I, No. 4-5, pp 447-452, XP002080949 (Oct. 1990)	
GW	CB	OKAJIMA, K. et al., Direct Evidence for Systematic Fibrinogenolysis in a Patient with Metastatic Prostatic Cancer, <i>Thrombosis Research</i> , Vol. 66, No. 6, pp 717-727, XP002080950 (June, 1992)	
GW	CC	MC CABE, R. P., et al., Monoclonal Antibodies in the Detection of Bladder Cancer, <i>Immunology Series</i> , Vol. 39, pp 1-29, XP002080951	
GW - abstract only	CD	SCHWARZ, H. P., et al., Fibrinolyse-Inhibitoren und Fibrinogensplattprodukte bei Patienten mit Malignen Erkrankungen, <i>ACTA Medica Austriaca</i> , Vol. 8, No. 1, pp 22-25, XP002080952	
GW	CE	HUI, K.Y. et al., Monoclonal Antibodies to a Synthetic Fibrin-Like Peptide Bind to Human Fibrin but Not Fibrinogen, <i>Science</i> , Vol. 222, pp 1129-1132, XP002080953 (1983)	
GW	CF	KUDRYK, B. et al., Specificity of a Monoclonal Antibody for the NH2-terminal Region of Fibrin, <i>Molecular Immunology</i> , Vol. 21, PP 89-94, XP002081107 (1984)	
GW	CG	WHUR, P. et al., Fibrinolysis in Lung Cancer, <i>European Journal of Cancer</i> , Vol. 14, No. 3, pp 315-316, XP002080954, (February, 1978)	

Examiner
Signature

[Signature]

Date
Considered

6/6/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.